Modern Toxicity Management and Patient Education

Dr. Rodriguez outlines patient education strategies emphasizing partnership from treatment initiation, as clinical trials demonstrate over half of patients require dose adjustments. Critical communication includes instructions not to allow side effects to continue without intervention, promoting dose interruptions to maintain long-term treatment capability. Patients frequently contact providers on weekends when team members may lack ROS1 expertise, requiring clear guidance that temporary dose holds are acceptable until reconnection with the primary team, while ensuring patients have appropriate supportive care medications at home.

Dr. Leal discusses novel agents including zongertinib showing promising early-phase data with high ROS1 selectivity avoiding TRKB effects and associated neurotoxicity. The most prominent reported toxicity involves peripheral edema in 15% or greater of patients, with overall better tolerability compared to earlier-generation ROS1 TKIs and low-grade AST/ALT abnormalities. More comprehensive toxicity data is expected from ongoing phase 2 studies.

The key takeaway emphasizes significant overlap in ROS1 potency among agents but very different expected adverse effect profiles. Initiating patients on these agents requires awareness of unique distinctions for appropriate counseling and monitoring, helping patients successfully remain on treatment to achieve potential long-term efficacy benefits. Community oncologists familiar with older agents like crizotinib should understand that newer drugs offer substantial survival advantages with manageable toxicities comparable to other daily-use medications, with company-provided guidance for dose adjustments and holds.

Team education remains crucial, including nursing staff receiving triage calls and clinical pharmacists providing patient counseling. Pre-treatment education sessions outline expectations, warning signs, timing for contact, and supportive care guidance. For taletrectinib specifically, ensuring patients have antiemetics and antidiarrheal medications before treatment initiation, with clear instructions about when to contact providers, helps prevent symptom escalation during the critical first month when gastrointestinal side effects are most likely to occur.